- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02848482
Anti-infective Effect of Non-surgical Treatment With and Without Photodynamic Therapy on Initial Peri-implantitis
Anti-infective Effect of Non-surgical Treatment With and Without Photodynamic
Photodynamic therapy (PDT), also known as photoradiation therapy, phototherapy, or photochemotherapy, involves the use of a photoactive dye (photosensitizer) that is activated by exposure to light of a specific wavelength in the presence of oxygen. In recent years, PDT has been introduced as an important novel disinfection therapy in the field of implant dentistry. The inactivation of microorganisms using PDT has been defined as antimicrobial PDT. PDT has the potential to be an alternative of antibiotics, especially for the treatment of localized infections and oral biofilm. PDT is unlikely to cause bacterial-resistance and is equally effective against antibiotic-resistance and antibiotic-susceptible bacteria.
Inconsistent results have been reported regarding the potential role of PDT as an adjunct to mechanical debridement in the management of peri-implant infection. Thus, the aim of the present trial is to investigate the treatment effect of non-surgical treatment with and without photodynamic therapy on initial peri-implantitis.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200011
- Shanghai Ninth People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects, ages over 18.
- Subjects with at least one implant with initial peri-implantitis: PPD of 4-6mm combined with BOP+, bone loss of 0.5-2mm on peri-apical radiographs compared to the time point of restoration placement.
- Availability for the 12 month duration of the study.
- Good general health (ASA classification I-II).
- Signed Informed Consent Form.
Exclusion Criteria:
- Medically compromised subjects (ASA classification III-V)
- Pregnant or lactating females.
- Peri-implant mucositis defined as the absence of radiographic marginal bone loss between restoration placement and pre-screening review.
- Subjects treated for >2 weeks with any medication known to affect soft tissue condition (e.g. phenytoin, calcium antagonists, cyclosporin, Coumadin and non-steroidal anti-inflammatory drugs) within 1 month of the baseline examination.
- Unwilling to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control group
Plastic curette will be used to perform the mechanical debridement.
Then, irrigation (2% chlorhexidine) will be performed at contaminated sites.
|
Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
|
Experimental: Test group
Plastic curette will be used to perform the mechanical debridement.
Then, the addition photodynamic therapy (PDT) will be performed.
This will be performed with a set-up for PDT (HELBO Photodynamic Systems, German).
|
Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of percentage of bleeding on probing sites
Time Frame: From baseline to 12 months after treatment
|
A PQW Williams probe (Hu-Friedy, Chicago Ill, USA)will be used to detect the peri-implant pocket.
the percentage of bleeding on probing sites (BOP) will be recorded.
|
From baseline to 12 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Probing Pocket Depth
Time Frame: From baseline to 12 months after treatment
|
Probing Pocket Depth at every site will be assessed as the distance from the gingival margin to the apical end of the pocket using a PQW Williams probe (Hu-Friedy, Chicago Ill, USA).
|
From baseline to 12 months after treatment
|
Change of modified plaque index
Time Frame: From baseline to 12 months after treatment
|
Modified plaque index 0= No detection of plaque.
|
From baseline to 12 months after treatment
|
Change of clinical attachment level
Time Frame: From baseline to 12 months after treatment
|
From baseline to 12 months after treatment
|
|
Marginal bone loss
Time Frame: From baseline to 12 months after treatment
|
Periapical radiographs will be taken at baseline, 3, 6, 9 and 12 month examination.
The distance from implant shoulder to the most coronal level of implant-bone contact at the mesial and distal site will be recorded.
The alteration of the distance between baseline and follow-up visit will be defined as marginal bone loss.
|
From baseline to 12 months after treatment
|
Mucosa recession
Time Frame: From baseline to 12 months after treatment
|
The distance from mucosa margin to the implant shoulder will be recorded using a PQW Williams probe (Hu-Friedy, Chicago Ill, USA).
The alteration of the distance between baseline and follow-up visit will be defined as the mucosa recession.
|
From baseline to 12 months after treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1036_2016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peri-implantitis
-
PolyPid Ltd.MIS Implant Technologies, LtdCompleted
-
University of ManitobaUnknownPeri ImplantitisCanada
-
University of ValenciaCompletedEarly Apical Peri-implantitis
-
Rambam Health Care CampusRecruitingDental Implants,Peri-implantitis,SmokingIsrael
-
Tuğba ŞAHİNCompletedPeri-Implantitis, Peri-implant MucositisTurkey
-
Proed, Torino, ItalyCompleted
-
University of ZagrebNot yet recruitingPeri-implant Mucositis | Peri-Implantitis and Peri-implant Mucositis | Peri-implant Health | Periimplant Diseases | Periimplant Bone Loss
-
National and Kapodistrian University of AthensRecruitingPeri-Implantitis | Peri-Implant HealthGreece
-
Center of Implantology, Oral and Maxillofacial...Recruiting
-
University of BaghdadRecruiting
Clinical Trials on Mechanical debridement
-
Smith & Nephew, Inc.TerminatedTorn MeniscusUnited States
-
National Taiwan University HospitalUnknown
-
University of MichiganMorita J USACompleted
-
University of MichiganWithdrawn
-
Smith & Nephew, Inc.TerminatedChondral Lesion Plus Partial Medial MeniscectomyUnited States
-
Federal University of São PauloUnknownInflammation | Meibomian Gland Dysfunction | Dry Eye Disease | Evaporative Dry Eye | Tear Film DeficiencyBrazil
-
ArthroCare CorporationCompletedAchilles Pain | Achilles Tendinosis | Heel PainUnited States
-
Christopher KaedingSmith & Nephew, Inc.TerminatedArticular Cartilage Disorder of KneeUnited States
-
BSN Medical GmbHCompleted
-
Kerman Medical UniversityCompletedDIABETIC FOOT ULCERS